Request More Information

Simoa® Neurology Assays & Services

 

From discovery to diagnostics, our Simoa assays and custom assay development services can fuel your research through the ability to identify and examine critical biomarkers less invasively, more efficiently, and with higher accuracy when compared to other analog methods. 

Simoa assays can detect neurological biomarkers, such as neurofilament light (NfL), Tau, GFAP, and several others associated with brain injury and disease, in blood, serum or plasma. The ability to detect neurological biomarkers at ultra-low levels in blood, serum or plasma, which have traditionally only been detectable in cerebrospinal fluid, has the potential to completely transform the way brain injuries and diseases are detected and diagnosed.

Jump to form

Scientist with Simoa HD-X

Fueling the Driving Force in Brain Health Research

We work with a rapidly growing network of academic researchers and pharmaceutical and biotech partners to drive advancements in head health research, and you could be next.
 
Quanterix can support your strategic focus in: 

  • Neurodegeneration
  • Neuroinflammation
  • Traumatic brain injuries (TBI) 
  • Multiple sclerosis (MS)
  • Alzheimer's disease (AD)

Our Recent Successes: 

  • Our latest laboratory developed test – the first pTau-181 plasma test released for clinical use in the U.S. – is a quantitative immunoassay intended for the measurement of pTau-181 concentration in human plasma to aid in the diagnostic evaluation of AD when used in conjunction with other diagnostic tools. 
  • Our Simoa NfL plasma test has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) as a prognostic aid in assessing the risk of disease activity in patients diagnosed with relapsing-remitting MS (RRMS) when used in conjunction with other diagnostic tools. 
  • Researchers found that plasma NT1 levels predicted future pathological tau accumulation, cognitive decline and neurodegeneration, suggesting that the marker may be indicative of early changes in the development of AD, all using a Simoa® Homebrew assay.1

Learn more about the technology and expertise we can supply to fuel your research. 

By submitting the form you agree to Quanterix’s Terms and Conditions. If you have subscribed to our email marketing you can unsubscribe at any time, and you can learn more about how we manage your personal details in our Privacy Policy.

Our Current Portfolio

Quanterix offers the flexibility to meet you where your team and research are at.

Simoa Accelerator Lab

Simoa® Accelerator Laboratory

Utilize our CLIA-certified laboratory as a cost-effective, outsourced solution for your custom biomarker and biopharmaceutical research, assay development, and clinical sample testing.

Simoa Assays

NF-LightTM Assay

The Simoa NF-LightTM assay is a digital immunoassay for the quantitative determination of NfL in serum, plasma, and CSF. The antibodies also cross react with murine, bovine, and macaque NfL epitopes, and the assay can be used for research with these species.

Simoa Homebrew Assay

Simoa® Homebrew Assays

Quanterix offers the flexibility of multiplex homebrew assay development to minimize required sample volume; providing full kits that include all reagents and training required to develop these custom homebrew assays.